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Successful right atrial 
thrombus lysis with 
alteplase in a nine month 
old infant
ABSTRACT
Objective. To present the case of an infant with a catheter related atrial thrombus resolved with local instillation of alteplase. 
Clinical presentation. Echocardiography (ECHO) was performed in an infant with sepsis to estimate cardiac contractility, and 
a large mobile thrombus (28 x 8 mm) was detected in the right atrium. A left subclavian, double lumen, central venous line 
(CVL, 4 French, 8 cm), inserted 10 weeks previously, was left in place. Standard treatment with enoxaparine was commen-
ced twice daily for 10 days at a dose of 1 mg/kg. Repeat ECHO showed no changes in thrombus size or mobility. Therefore, 
alteplase was administered into the distal catheter (1 mg in normal saline) at a dose of 110% of its priming volume. The 
dwelling time was 2 hours. Since no changes in thrombus size were observed, the same dose was given into the proximal 
catheter. ECHO performed 24 hours later showed a significant reduction in thrombus size. The third dose of alteplase was 
administered into the proximal catheter. ECHO showed complete dissolution of the right atrial thrombus. No bleeding was 
observed during and following therapy, and there were no signs of hemodynamic instability. The CVL was safely removed 
the same day and no endoluminal thrombus was seen. 
Conclusion. Local instillation of alteplase in three doses was a safe and effective approach to the management of a large 
catheter-related intraatrial thrombus. Systemic thrombolytic therapy, associated with an increased risk of bleeding, and 
open heart surgery were avoided. 
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Introduction
The care and treatment of children with 
acute or chronic diseases has been 
facilitated by the use of central venous 
lines (CVL). Partial or total occlusion of 
CVLs and catheter-related thrombosis 
are common complications. Catheter-
related thrombosis occurs more often 
in children with long-term CVLs (when 
even 50% of them can be asymptomat-
ic). (1) The KIDCAT (Kids with Catheter-
Associated Thrombosis) study showed 
that the incidence of thrombosis in chil-
dren with short-term central venous 
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catheters was 28% and 20% of them 
had clinical symptoms or had devel-
oped CVL occlusion. (2)
Formation of a right atrial thrombus in 
a child with a normal heart is rare. The 
presence of a CVL and systemic infec-
tion are the most important risk factors 
for the development of intraatrial throm-
bosis. If the thrombus is mobile, there is 
a significant risk of massive pulmonary 
embolism. 
Case report
A 9-month old female infant was hos-
pitalized in the Pediatric Intensive Care 
Unit because of an unclassified neu-
romuscular disorder. During the first 
few months of life echocardiography 
(ECHO) was normal on several occa-
sions.
After three weeks in hospital, acquired 
Klebsiella pneumoniae sepsis was diag-
nosed. A central line (4Fr, 8 cm) was 
inserted through the left subclavian vein. 
Chest radiography showed that the tip 
of the line was correctly placed at the 
junction of the vena cava superior and 
right atrium. Two weeks later ECHO was 
performed to assess cardiac contractil-
ity and a large floating intraatrial mass 
was visualized (figure 1). There were no 
signs of hemodynamic compromise. 
Platelet count and blood coagulation 
tests, including antithrombin III, were 
normal.  D-dimer was slightly elevated 
(1.92 mcg/L).  Magnetic resonance 
imaging of the heart showed that the 
intraatrial mass was a catheter-related 
intraatrial thrombus 28x8 mm in size. 
The CVL was left in place and treat-
ment with low-weight molecular heparin 
(enoxaparine) was initiated at a dos-
age of 1 mg/kg every 12 hours. ECHO 
performed after ten days of treatment 
with enoxaparine showed no signs of 
improvement. Cardiac surgeons were 
consulted, and treatment with tissue 
plasminogen activator (alteplase) was 
initiated. The risks of thrombolytic 
therapy were explained to the parents 
and informed consent was signed. The 
dose of alteplase was 110% of prim-
ing volume (1 mg in 1 mL of normal 
saline), and was administered into the 
distal catheter. The dwelling time was 2 
hours. Subsequent ECHO showed no 
changes in thrombus size, so a second 
dose of alteplase was administered 
into the proximal catheter. After another 
two hours, ECHO showed significant 
reduction in thrombus size. The third 
dose of alteplase was administered into 
the proximal catheter 24 hours later. 
After a dwelling time of 2 hours, ECHO 
revealed complete resolution of the 
thrombus (figure 2). 
There were no signs of pulmonary embo-
lism or bleeding during and following the 
fibrinolytic therapy. The CVL was safely 
removed. Factor V Leiden, factor II pro-
thrombin and methylenetetrahydrofo-
late reductase (MTHFR) were all normal. 
Therapy with enoxaparine continued at 
a prophylactic dose (0.5 mg/kg twice 
daily) for the next three months. 
Discussion
There are no clear recommendations 
for a therapeutic approach to organized 
catheter-related intraatrial thrombi. The 
standard treatment for occluded CVLs 
is local instillation of alteplase with the 
maximum dose of 2 mg/2 mL. When 
the volume of the catheter is less than 
2 mL, the recommended dose is 110% 
Figure 1.  Echocardiography showed an intraatrial thrombus (28 x 8 mm) befo-
re fibrinolytic treatment.
Figure 2.  Complete dissolution of the intraatrial thrombus after the third dose 
of alteplase. 
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of its volume. (1) The COOL study (Car-
diovascular thrombolytic used to Open 
Occluded Lines) showed that fibrin-
olysis with alteplase in adults and in 
children with obstructed CVLs is a safe 
and effective therapeutic procedure, 
with overall catheter clearance rates 
of 83-87% and no adverse outcomes 
documented. (3,4) The Cathflow Pedi-
atric Study Group reported that none of 
310 patients under the age of 17 treated 
with local instillation of alteplase experi-
enced intracranial hemorrhage. (5)  
 Fibrinolytic activity of alteplase is based 
on its catalytic effect on the conversion 
of plasminogen into plasmin. Therefore, 
there are suggestions to give fresh fro-
zen plasma before alteplase therapy in 
young infants and in cases of plasmino-
gen deficiency. (6) 
According to the evidence-based clini-
cal practice guidelines of the American 
College of Chest Physicians, in regard 
to the most commonly used local and 
systemic dose regimens for throm-
bolytic therapy in pediatric patients, 
alteplase is the treatment of choice in 
patients who require fibrinolysis. (6) 
Published series recommend alteplase 
infusion from low dose (0.01 mg/kg/h) 
to high dose (0.6 mg/kg/h), with the 
reported bleeding risk varying from 3 
to 27%. (7,8) However, the optimum 
doses for children are not known.  Suc-
cessful treatment of a large intracardial 
thrombus using escalating tissue plas-
minogen activator infusions (0.1-0.25 
mg/kg/h) without bleeding complica-
tions has been reported. (9) There is 
also no evidence about the advantage 
of systemic over local thrombolytic 
therapy.  
In this reported case, the intraatrial 
thrombus was large and organized. As 
the blood could not be aspirated from 
the catheter about two weeks before 
diagnostic ECHO, we can speculate 
that the thrombus was present for at 
least a week. Since there were no signs 
of hemodynamic instability, treatment 
with low-weight molecular heparin was 
administered for ten days. When con-
sidering initial fibrinolytic therapy with 
alteplase, we preferred its local instil-
lation rather than systemic infusion, 
because of less reported complica-
tions. (6) Although a number of studies 
have reported a low incidence (modest 
benefit of 19% or less) of successful 
thrombus resolution after the second 
dose of local instillation of alteplase, 
(5,10)  in our case a significant reduc-
tion in thrombus size was observed. 
Furthermore, the third dose of alteplase 
resulted in complete dissolution of the 
thrombus.
Conclusion
The local instillation of alteplase in doses 
recommended for catheter obstruction 
was successful in management of a 
large, mobile catheter-related intraatrial 
thrombus. This seems to be a reason-
able therapeutic option even if the throm-
bus is large and already organized. The 
dwelling time should be at least two 
hours with subsequent echocardio-
graphic and hematologic assessment. 
If partial reduction of thrombus size is 
obtained after two doses of alteplase, 
the third dose could be effective. Thus, 
the high risk of bleeding, as a compli-
cation of systemic fibrinolytic therapy, 
seems to be avoidable.
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